NICE guidance on the Prevention and management of neutropenic sepsis in cancer patients [CG151]
This NICE guidance outlines recommendations for the prevention, identification and management of neutropenic sepsis in people with cancer. It focuses on the crucial steps needed to protect patients, particularly children, young people, and adults undergoing cancer treatment, from the serious complications associated with neutropenic sepsis, both in community settings and within secondary and tertiary care facilities.
The guideline provides comprehensive strategies aimed at reducing the risk of infection in individuals with neutropenia, a condition characterised by a low white blood cell count resulting from anticancer therapies. By highlighting effective preventative measures, early detection methods, and prompt management protocols, this guidance seeks to improve clinical outcomes for those affected.
Key recommendations include implementing robust infection control practices, educating healthcare professionals on the signs and symptoms of neutropenic sepsis, and ensuring timely access to appropriate medical interventions. The guidance also emphasises the importance of individualised care plans tailored to each patient’s unique circumstances, enabling healthcare providers to respond effectively to the needs of patients at risk.
Use Case
Type
Source
You might also like
IMWG immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
Step into the forefront of myeloma treatment with this latest publication from the International Myeloma Working Group immunotherapy committee.
IMWG GuidelineBSH/UKMS good practice paper on Diagnosis and management of smouldering myeloma
Explore the latest guidelines for Smouldering Myeloma care in the British Society for Haematology Good Practice Paper.
BSH GuidelineNICE guidelines on Spinal metastases and metastatic spinal cord compression [NG234]
This NICE guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC).
NICE GuidelineIMWG recommendations on the management of multiple myeloma-related renal impairment
The IMWG outline updates to clinical practice guidance for the management of multiple myeloma-related renal impairment.
IMWG GuidelineIMWG consensus guidelines and recommendations for infection prevention in myeloma
Infection poses a significant risk to patients with multiple myeloma, contributing to high rates of morbidity and mortality. This consensus statement from the International Myeloma Society outlines essential guidelines for infection prevention
IMWG GuidelineBSH/UKMS guidelines on the Diagnosis, investigation, and initial treatment of myeloma
These new guidelines, produced by the British Society for Haematology (BSH) and the UK Myeloma Society (UKMS), provide healthcare professionals with guidance on the anti-myeloma management of patients with newly diagnosed myeloma.
IMWG recommendations for the treatment of multiple myeloma-related bone disease
This guideline, authored by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the current evidence and offers management recommendations for myeloma-related bone disease.
IMWG GuidelineNICE guideline on Acute kidney injury: prevention, detection and management [NG148]
This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
NICE GuidelineIMWG consensus recommendations on imaging in monoclonal plasma cell disorders
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
IMWG GuidelineMY-RADS guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma
As whole-body MRI is listed in NICE guidance as the recommended first line imaging in patients with suspected myeloma, this paper outlines a clinical protocol: the Myeloma Response Assessment and Diagnosis System (MY-RADS), for its use and interpretation.
Other Guideline
